Moderna, Skyworks Solutions, and Illumina face downward pressure as analyst consensus suggests these S&P 500 stocks are trading at least 7% above their 12-month price targets.
Analysts consider Moderna overvalued by 7% or more relative to its 12-month price target.
Analysts consider Skyworks Solutions overvalued by 7% or more relative to its 12-month price target.
Analysts consider Illumina overvalued by 7% or more relative to its 12-month price target.
Wall Street analysts are signaling caution on several S&P 500 constituents, identifying Moderna, Skyworks Solutions, and Illumina as significantly overvalued. Current market data suggests these stocks are trading at least 7% above their respective 12-month price targets.
Analysts have determined that the current market prices for Moderna, Skyworks Solutions, and Illumina exceed their projected 12-month price targets by at least 7%.